Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model

Evaluation of a potential risk of metabolic drug–drug interactions (DDI) is of high importance in the clinical setting. In this study, a physiologically based pharmacokinetic (PBPK) model was developed for oxycodone and its two primary metabolites, oxymorphone and noroxycodone, in order to assess di...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:CPT Pharmacometrics Syst Pharmacol
Egile Nagusiak: Marsousi, N, Daali, Y, Rudaz, S, Almond, L, Humphries, H, Desmeules, J, Samer, C F
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2014
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4288002/
https://ncbi.nlm.nih.gov/pubmed/25518025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/psp.2014.49
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak